110 related articles for article (PubMed ID: 1709841)
1. Gonadotrophin releasing hormone agonist suppressive treatment of ovarian function decreases serum LH-beta and bioactive LH but maintains elevated levels of LH-alpha.
Lemay A; Lourdusamy M
Clin Endocrinol (Oxf); 1991 Mar; 34(3):191-6. PubMed ID: 1709841
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
Masaoka K; Kitazawa M; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
[TBL] [Abstract][Full Text] [Related]
3. [Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].
Masaoka K; Kitazawa M; Watanabe H; Kumasaka T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):729-36. PubMed ID: 2504848
[TBL] [Abstract][Full Text] [Related]
4. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
[TBL] [Abstract][Full Text] [Related]
5. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
[TBL] [Abstract][Full Text] [Related]
6. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
[TBL] [Abstract][Full Text] [Related]
7. Studies on GnRH agonist suppression of estrogen production in patients with endometriosis.
Ohtsuka S; Terakawa N; Shimizu I; Sakata M; Mizutani T; Miyake A; Tanizawa O; Aono T
Endocrinol Jpn; 1989 Aug; 36(4):611-9. PubMed ID: 2510993
[TBL] [Abstract][Full Text] [Related]
8. Prolonged treatment with the GnRH analogue buserelin does not affect alpha-subunit production by the pituitary gonadotroph.
Kwekkeboom DJ; Lamberts SW; Blom JH; Schroeder FH; De Jong FH
Clin Endocrinol (Oxf); 1990 Apr; 32(4):443-51. PubMed ID: 1693322
[TBL] [Abstract][Full Text] [Related]
9. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
Huhtaniemi IT; Dahl KD; Rannikko S; Hsueh AJ
J Clin Endocrinol Metab; 1988 Feb; 66(2):308-13. PubMed ID: 3123510
[TBL] [Abstract][Full Text] [Related]
10. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
Lemay A; Maheux R; Huot C; Blanchet J; Faure N
Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
[TBL] [Abstract][Full Text] [Related]
12. Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.
Damjanović S; Micić D; Popović V; Petakov M; Kendereski A; Sumarac M; Manojlović D; Mićić J
J Endocrinol Invest; 1991 Apr; 14(4):299-304. PubMed ID: 1713932
[TBL] [Abstract][Full Text] [Related]
13. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
14. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
16. The hypothalamic-pituitary-ovarian axis in patients with endometriosis is suppressed by leuprolide acetate but not by danazol.
Sakata M; Ohtsuka S; Kurachi H; Miyake A; Terakawa N; Tanizawa O
Fertil Steril; 1994 Mar; 61(3):432-7. PubMed ID: 8137962
[TBL] [Abstract][Full Text] [Related]
17. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of a gonadotrophin-releasing hormone agonist ([D-Ser(But)6]GnRH(1-9)nonapeptide-ethylamide) on gonadotrophin secretion from human pituitary gonadotroph cell adenomas in vitro.
Daniels M; Newland P; Dunn J; Kendall-Taylor P; White MC
J Endocrinol; 1988 Sep; 118(3):491-6. PubMed ID: 2460576
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
20. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
